MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical immunology"
DOI: 10.1016/j.clim.2019.04.004
Abstract: OBJECTIVE To determine the role of the NLRP3 inflammasome by using the selective NLRP3 inhibitor MCC950 in patients with NLRP3 low penetrance variants and clinical symptoms suggestive for an autoinflammatory syndrome including central nervous system… read more here.
Keywords: patients nlrp3; nlrp3 low; penetrance; low penetrance ... See more keywords